通过抑制 JAK 来控制免疫细胞。
Get a grip on immune cells by inhibiting JAKs.
机构信息
Department of Internal Medicine III, Oncology, Hematology and Rheumatology, University Clinic Bonn (UKB) , Bonn, Germany.
Department of Internal Medicine III, Oncology, Hematology and Rheumatology, University Clinic Bonn (UKB), Bonn, Germany; Laboratory for Tumorimmunology, Department of Medicine V, Medical University Innsbruck, Innsbruck, Austria.
出版信息
Oncoimmunology. 2015 Aug 12;5(2):e1071009. doi: 10.1080/2162402X.2015.1071009. eCollection 2016 Feb.
Abstract
JAK inhibitors are approved for myelofibrosis (MF) and polycythemia vera (PV), as they reverse inflammation-associated splenomegaly and symptoms. Notably, JAK inhibitors only marginally affect disease burden. The anti-inflammatory effects of JAK inhibitors affects DC, T and NK cells explaining their therapeutic potential for limitation of cancer-associated inflammation, Graft--Host Disease (GvHD) and autoimmunity.
摘要
JAK 抑制剂已获批用于骨髓纤维化 (MF) 和真性红细胞增多症 (PV)，因为它们可逆转与炎症相关的脾肿大和症状。值得注意的是，JAK 抑制剂仅轻微影响疾病负担。JAK 抑制剂的抗炎作用影响 DC、T 和 NK 细胞，解释了它们在限制癌症相关炎症、移植物抗宿主病 (GvHD) 和自身免疫方面的治疗潜力。
相似文献
1
Get a grip on immune cells by inhibiting JAKs.
Oncoimmunology. 2015 Aug 12;5(2):e1071009. doi: 10.1080/2162402X.2015.1071009. eCollection 2016 Feb.
2
Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors.
J Hematol Oncol. 2012 Aug 1;5:43. doi: 10.1186/1756-8722-5-43.
3
Ruxolitinib.
Recent Results Cancer Res. 2018;212:119-132. doi: 10.1007/978-3-319-91439-8_6.
4
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
Cancer Chemother Pharmacol. 2016 Jun;77(6):1125-42. doi: 10.1007/s00280-016-3012-z. Epub 2016 Mar 26.
5
Treatment and management of myelofibrosis in the era of JAK inhibitors.
Biologics. 2013;7:189-98. doi: 10.2147/BTT.S34942. Epub 2013 Aug 20.
6
Recent progress of JAK inhibitors for hematological disorders.
Immunol Med. 2023 Sep;46(3):131-142. doi: 10.1080/25785826.2022.2139317. Epub 2022 Oct 28.
7
Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms.
Cancers (Basel). 2020 Oct 9;12(10):2891. doi: 10.3390/cancers12102891.
8
The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation.
Intern Med. 2017;56(13):1705-1710. doi: 10.2169/internalmedicine.56.7871. Epub 2017 Jul 1.
9
Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.
Br J Haematol. 2013 Aug;162(3):326-35. doi: 10.1111/bjh.12384. Epub 2013 May 23.
10
Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives.
Int J Hematol. 2022 May;115(5):626-644. doi: 10.1007/s12185-022-03335-7. Epub 2022 Mar 29.
引用本文的文献
1
Clinical and Immune Effects of Peri-Transplantation JAK Inhibition for Myelofibrosis.
Am J Hematol. 2025 Feb;100(2):200-209. doi: 10.1002/ajh.27529. Epub 2024 Nov 16.
2
Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios.
Cancers (Basel). 2021 Sep 23;13(19):4750. doi: 10.3390/cancers13194750.
3
The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis.
Oncoimmunology. 2020 Jun 23;9(1):1782575. doi: 10.1080/2162402X.2020.1782575.
本文引用的文献
1
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.
J Clin Oncol. 2015 Dec 1;33(34):4039-47. doi: 10.1200/JCO.2015.61.4578. Epub 2015 Sep 8.
2
JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms.
Cancer Res. 2015 Jun 1;75(11):2187-99. doi: 10.1158/0008-5472.CAN-14-3198. Epub 2015 Apr 1.
3
JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms.
Br J Haematol. 2015 Jun;169(6):824-33. doi: 10.1111/bjh.13373. Epub 2015 Mar 30.
4
Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease.
Blood. 2014 Jun 12;123(24):3832-42. doi: 10.1182/blood-2013-12-543736. Epub 2014 Apr 7.
5
Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?
Blood. 2013 Nov 28;122(23):3843-4. doi: 10.1182/blood-2013-10-531103.
6
The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo.
Blood. 2013 Aug 15;122(7):1192-202. doi: 10.1182/blood-2013-03-484642. Epub 2013 Jun 14.
7
Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells.
J Clin Invest. 2012 Jul;122(7):2369-83. doi: 10.1172/JCI58457. Epub 2012 Jun 11.
8
JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation?
Anticancer Agents Med Chem. 2012 Nov;12(9):1098-109. doi: 10.2174/187152012803529727.
9
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
N Engl J Med. 2012 Mar 1;366(9):799-807. doi: 10.1056/NEJMoa1110557.
10
The V617F JAK2 mutation and the myeloproliferative disorders.
Hematol Oncol. 2005 Sep-Dec;23(3-4):91-3. doi: 10.1002/hon.761.
Zotero 插件